Pharmafile Logo
Pharmafocus logo
Advanced Search

cannabidiol

Showing 11 posts of 11 posts found.

insider_interview_andrew_roach

A new weapon against Parkinson’s-related psychosis

December 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma

Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …

Feature
https__cdn

NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy

August 27, 2019
Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …

News
16792957331_d9572dbdf4_z

FDA issues warning to CBD company Curaleaf

July 29, 2019
Sales and Marketing CBD, FDA, cannabidiol, curaleaf, pharma, regulation

The FDA has issued a warning to Massachusetts-based CBD company Curaleaf over the firm’s use of unsubstantiated claims about the …

News
cannabis-2152604_960_720

Synthetic, non-intoxicating CBD analogue treats seizures in rats

May 31, 2019
Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma

A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …

News
gwpharma

GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial

May 7, 2019
Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc

GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …

News
gwpharma

GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States

November 2, 2018
Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis

GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …

News
gwpharma

GW Pharma’s Epidiolex becomes first cannabis-based medicine available in US

June 26, 2018
Manufacturing and Production, Sales and Marketing FDA, GW Pharma, Lennox-Gastaut syndrome, UK, US, cannabidiol, cannabis

In what could prove to be a pivotal decision, UK biotech GW Pharmaceuticals has announced that its oral cannabidiol solution …

News

FDA issues warnings in crackdown on baseless cannabis miracle cures

November 2, 2017
Research and Development, Sales and Marketing FDA, cannabidiol, cannabis, pharma

The FDA has issued a warning over cannabis-based therapies which promise the ability to cure cancer, asserting that such treatments …

News
cannabidiol

Cannabidiol reduces seizures by half in severe epilepsy, study suggests

April 19, 2017
Research and Development Lennox-Gastaut syndrome, cannabidiol

A new large-scale study from the American Academy of Neurology has suggested that cannabidiol, a molecule derived from cannabis without …

News
gwpharma

Cannabis-based treatment scores Phase 3 successes for GW Pharma

December 6, 2016
Manufacturing and Production, Research and Development GW Pharma, cannabidiol

UK-based GW Pharmaceuticals, a biopharmaceutical firm focused on the development of novel cannabinoid therapies, has unveiled new efficacy data for …

News
Sativex image

Late-stage failure for Otsuka and GW cancer pain drug

January 9, 2015
Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024